Picture of Hikma Pharmaceuticals logo

HIK Hikma Pharmaceuticals News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareBalancedLarge CapNeutral

REG - Hikma Pharmaceutical - Directorate Change

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220224:nRSX6318Ca&default-theme=true

RNS Number : 6318C  Hikma Pharmaceuticals Plc  24 February 2022

Hikma Pharmaceuticals PLC - Board and Committee Changes

 

 

London, 24 February 2022 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK)
(Hikma) announces the following changes to its board of directors and their
responsibilities:

 

·      Dr. Pamela Kirby has decided not to stand for re-election at the
next annual general meeting of the Company that is scheduled to take place on
25 April 2022; and

 

·      Nina Henderson will take over as chair of the Remuneration
Committee with effect from the end of the annual general meeting.

 

Said Darwazah, Executive Chairman, said: 'I am very grateful to Pam for her
leadership of the Remuneration Committee and the considerable value that she
has added to the Board, particularly in relation to her expert knowledge of
the pharmaceutical sector.  I wish Pam well for the future.  I am pleased
that Nina has agreed to lead the Remuneration Committee going forward. Nina
brings to the role a wealth of remuneration experience and a deep
understanding of Hikma.'

 

 

 

-- ENDS --

 

Enquiries:

 

Hikma Pharmaceuticals PLC

Peter Speirs, Company
Secretary
+44 (0)20 7399 2772

Susan Ringdal, EVP Strategy and Global Affairs
                                     +44 (0)20 7399
2760

 

About Hikma

 

Hikma helps put better health within reach every day for millions of people
around the world. For more than 40 years, we've been creating high-quality
medicines and making them accessible to the people who need them.
Headquartered in the UK, we are a global company with a local presence across
the United States (US), the Middle East and North Africa (MENA) and Europe,
and we use our unique insight and expertise to transform cutting-edge science
into innovative solutions that transform people's lives. We're committed to
our customers, and the people they care for, and by thinking creatively and
acting practically, we provide them with a broad range of branded and
non-branded generic medicines. Together, our 8,700 colleagues are helping to
shape a healthier world that enriches all our communities. We are a leading
licensing partner, and through our venture capital arm, are helping bring
innovative health technologies to people around the world. For more
information, please visit: www.hikma.com (http://www.hikma.com)

 

 

(LEI:549300BNS685UXH4JI75)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAPPUGGPUPPGBW

Recent news on Hikma Pharmaceuticals

See all news